Article thumbnail

Functional polymorphisms in genes of the Angiotensin and Serotonin systems and risk of hypertrophic cardiomyopathy: AT1R as a potential modifier

By Eliecer Coto, María Palacín, María Martín, Mónica G Castro, Julián R Reguero, Cristina García, José R Berrazueta, César Morís, Blanca Morales, Francisco Ortega, Ana I Corao, Marta Díaz, Beatriz Tavira and Victoria Alvarez
Topics: Research
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:2907326
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2003). A: 5-Hydroxytryptamine 5-HT2A receptor and 5-hydroxytryptamine transporter polymorphisms in acute myocardial infarction. Clin Sci (Lond)
  2. (2009). Ackerman MJ: Diagnostic prognostic, and therapeutic implications of genetic testing for hypertrophic cardiomyopathy.
  3. (2005). Ackerman MJ: Gene-specific modifying effects of pro-LVH polymorphisms involving the renin-angiotensin-aldosterone system among 389 unrelated patients with hypertrophic cardiomyopathy. Eur Heart J
  4. (1999). Adnot S: Induction of serotonin transporter by hypoxia in pulmonary vascular smooth muscle cells. Relationship with the mitogenic action of serotonin. Circ Res
  5. (1998). AH: T1 receptor A/C1166 polymorphism contributes to cardiac hypertrophy in subjects with hypertrophic cardiomyopathy. Hypertension
  6. (1995). AJ: Angiotensin I converting enzyme genotypes and left ventricular hypertrophy in patients with hypertrophic cardiomyopathy. Circulation
  7. (1997). AJ: Role of candidate modifier genes on the phenotypic expression of hypertrophy in patients with hypertrophic cardiomyopathy.
  8. (2001). Alvarez V: Variation at the Angiotensin-converting enzyme and endothelial nitric oxide synthase genes is associated with the risk of esophageal varices among patients with alcoholic cirrhosis.
  9. (2000). Antonarakis SE: Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion. Hum Mutat
  10. (2007). Association between angiotensinogen, angiotensin II receptor genes, and blood pressure response to an angiotensin-converting enzyme inhibitor. Circulation
  11. (1995). Association between clozapine response and allelic variation in 5-HT2A receptor gene. Lancet
  12. (2004). BH: Genetic polymorphisms and heart failure. Genet Med
  13. (1996). Cambien F: Influence of angiotensinconverting enzyme and angiotensin II type 1 receptor gene polymorphisms on aortic stiffness in normotensive and hypertensive patients. Circulation
  14. (2000). Carabello BA: Left ventricular hypertrophy: pathogenesis, detection, and prognosis. Circulation
  15. (1998). Coto E: Angiotensin-converting enzyme and angiotensin II receptor 1 polymorphisms: association with early coronary disease. Cardiovasc Res
  16. (2003). Coto E: Hypertrophic cardiomyopathy: low frequency of mutations in the beta-myosin heavy chain (MYH7) and cardiac troponin T (TNNT2) genes among Spanish patients. Clin Chem
  17. (2007). Day IN: Quantitated transcript haplotypes (QTH) of AGTR1, reduced abundance of mRNA haplotypes containing 1166C (rs5186:A > C), and relevance to metabolic syndrome traits. Hum Mutat
  18. (1999). DL: Genetic variation in the serotonin transporter promoter region affects serotonin uptake in human blood platelets.
  19. (1993). G: 5HT2-receptors and serotonin release their role in human platelet aggregation. Life Sci
  20. (1996). GCM: Plasma angiotensin II, predisposition to hypertension, and left ventricular size in healthy young adults. Circulation
  21. (1996). Hashimoto K: Significance of angiotensin I-converting enzyme and angiotensin II type 1 receptor gene polymorphisms as risk factors for coronary heart disease. Atherosclerosis
  22. (2003). Hennekens CH: The renin-angiotensin system: the role of inhibitors, blockers, and genetic polymorphisms in the treatment and prevention of heart failure. Curr Vasc Pharmacol
  23. (2008). IW: Functional genetic polymorphisms in serotonin and dopamine gene systems and their significance in behavioural disorders. Prog Brain Res
  24. (1997). Izumo S: The cellular and molecular response of cardiac myocytes to mechanical stress. Annu Rev Physiol
  25. (2003). Maroteaux L: Functional consequence of serotonin/5-HT2B receptor signaling in heart: role of mitochondria in transition between hypertrophy and heart failure? Circulation
  26. (1997). ME: The angiotensin II type 1 receptor gene polymorphism is associated with coronary artery vasoconstriction.
  27. (2006). Molkentin JD: Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol
  28. (2009). Morís C: Mutations in sarcomeric genes MYH7, MYBPC3, TNNT2, TNNI3, and TPM1 in patients with hypertrophic cardiomyopathy. Rev Esp Cardiol
  29. (1997). Reiber JHC: Dell'Italia LJ. Angiotensinconverting enzyme inhibitor therapy affects left ventricular mass in patients with ejection fraction < 40% after acute myocardial infarction.
  30. (2000). S: Interleukin-6 family of cytokines mediate angiotensin II-induced cardiac hypertrophy in rodent cardiomyocytes.
  31. (1999). SB: Low- and high-level transgenic expression of beta2-adrenergic receptors differentially affect cardiac hypertrophy and function in Galphaq-overexpressing mice. Proc Natl Acad Sci USA
  32. (2009). Serotonin and angiotensin receptors in cardiac fibroblasts coregulate adrenergicdependent cardiac hypertrophy. Circ Res
  33. (2000). Staessen JA: Genetic polymorphisms in the renin-angiotensin system: relevance for susceptibility to cardiovascular disease.
  34. (1997). The influence of the angiotensin I converting enzyme genotype in familial hypertrophic cardiomyopathy varies with the disease gene mutation.
  35. (2008). WJ: Hypertrophic cardiomyopathy: the genetic determinants of clinical disease expression. Nat Clin Pract Cardiovasc Med